ScripOtsuka’s release of supplemental Phase III data on June 6 for sibeprenlimab was the second major data readout in immunoglobulin A nephropathy (IgAN) of the week, following Vera’s Phase III data on Jun
Pink SheetThe US Food and Drug Administration has successfully helped pull stalled cell and gene therapy programs off the cutting room floor in recent years and wants sponsors who might benefit from the agency’
ScripVera Therapeutics reported 36-week results on June 2 from the ORIGIN Phase III clinical trial of its B-cell modulator atacicept in the treatment of immunoglobulin A nephropathy (IgAN) in adults, showi
ScripWho: Eli Lilly/SiteOne Therapeutics What: Lilly has agreed to acquire privately held SiteOne and its Phase II-ready Nav1.8 inhibitor for pain for up to $1bn. Why: Pain is an area of therapeutic f